DeckTherapeutics appoints new CEO

The biotech entrepreneur Soren Weis Dahl, PhD, MBA today succeeded Suman Lal, MD, PhD, MBA as chief executive of DeckTherapeutics. Dr. Dahl successfully led the development and sale to Rallybio of two orphan drug assets (press release) and will oversee the development of THDG3 in the rare neonatal condition of HIE. Dr. Lal was instrumental in building DeckTherapeutics and the team after the spin-out from Columbia University and will continue to be part of the management team in his new role as Chief Operating Officer.